|
UCI |
|
BrainStorm Cell Therapeutics |
Amyotrophic Lateral Sclerosis (ALS) |
A phase 3, randomized, double-blind, placebo-controlled multicenter study to evaluate efficacy and safety of repeated administrations of NurOwn® (autologous mesenchymal stem cells secreting neurotrophic factors) in participants with ALS |
Recruiting |
|
UCI
& UC Davis |
|
Celularity, Inc. |
Hospitalized COVID-19 patients |
A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19 |
Recruiting |
|
|
UCI |
|
Cartesian Therapeutics |
MYASTHENIA GRAVIS (MG) |
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) |
Recruiting |
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) |
UCI
& UC Davis |
|
Humacyte |
Kidney failure |
A Phase 3 Study to Compare the Efficacy and Safety of Humacyte's Human Acellular Vessel With That of an Autologous Arteriovenous Fistula in Subjects With End Stage Renal Disease |
Recruiting |
|
|
UCI |
|
Pluristem Ltd. |
Critical Limb Ischemia (CLI) |
A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Phase III Study to Evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX-PAD for the Treatment of Subjects with Critical Limb Ischemia (CLI) with Minor |
Recruiting |
|
|
UCI |
|
ReNeuron Limited |
Stroke |
A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects with Disability Following an Ischemic Stroke (PISCES III) |
Recruiting |
|
|
UCLA |
|
UCLA |
Sickle Cell Disease |
Stem Cell Gene Therapy for Sickle Cell Disease |
Recruiting |
|
|
UCLA |
|
UCLA |
X-linked Chronic Granulomatous Disease |
Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease |
Recruiting |
|
|
UCLA |
Scott Nowicki, MD, PhD |
UCLA |
Cancer - Solid Tumors |
Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies |
Recruiting |
|
|
UCLA |
|
UCLA |
Cancer - Lung |
A Phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC |
Recruiting |
|
|
UCSD |
|
UCSD/Oncternal |
chronic lymphocytic leukemia |
Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax |
Recruiting |
Cirmtuzumab Consolidation for Treatment of Patients with Detectable CLL on Venetoclax |
|
UCSD |
|
Mesoblast |
Heart Failure |
The Purpose of This Study is to Evaluate the Efficacy and Safety of a Allogeneic Mesenchymal Precursor Cells (CEP-41750) for the Treatment of Chronic Heart Failure |
Recruiting |
|
|
UCSD |
|
Calibr |
Relapsed/Refractory B-cell Lymphomas |
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies |
Recruiting |
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies |
|
UCSD |
|
Viacyte |
Diabetes - Type 1 |
A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness |
Recruiting |
|
|
UCSD |
|
Calibr |
Relapsed/Refractory B-cell Lymphomas |
Long term follow-up study for patients administered CLBR001 , a CAR-T cell |
Recruiting |
Long term follow-up study for patients administered CLBR001 , a CAR-T cell |
|
UCSD |
|
Tigenix |
Crohn's Disease |
Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD) |
Recruiting |
Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of C |
|
UCSD |
|
UCSD & CIRM |
Cystinosis |
Stem cell gene therapy for cystinosis |
Recruiting |
Stem cell gene therapy for Cystinosis |
|
UCSD |
|
Neuralstem |
Spinal Cord Injury |
Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI |
Recruiting |
|
UCSD
& City of Hope |
|
UCSD |
Cancer - Leukemia |
A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies |
Recruiting |
|
|
UCSD |
|
Viacyte |
Diabetes - Type 1 |
Three Year Follow-up Safety Study in Subjects Previously Implanted With VC-01 |
Recruiting |
|
UCSF
& UC Davis |
|
|
COVID-19/ARDS |
Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative) |
Recruiting |
|
|
UCSF |
|
UCSF |
Blood Disorder - Alpha Thalassemia Major |
In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM) |
Recruiting |
|
UCSF
& UCSD & CIRM |
|
CIRM |
ARDS/COVID |
Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells (hMSCs) for the Treatment of Acute Respiratory Distress Syndrome (ARDS) |
Recruiting |
Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stromal Cells ( |
|
UCSF |
|
Editas Medicine Inc. |
Sickle Cell Disease |
A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell D |
Recruiting |
NCT04853576 |
|
UCSF |
|
Jasper Therapeutics |
Severe Combined Immunodeficiency syndrome |
A Phase 1 study to evaluate the safety and tolerability of tandemly-purified allogeneic CD34+CD90+ HSC administered following conditioning with JSP 191 to achieve engraftment and immune reconstitution in patients with SCID |
Recruiting |
|
|
UCSF |
|
CIRM & NHLBI |
Severe sickle cell disease |
Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease |
Recruiting |
|
|
UCSF |
|
Seattle Children's Hospital Foundation |
Cancer - Leukemia |
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia |
Recruiting |
NCT02028455 |
|
UCSF |
|
CRISPR Therapeutics |
B Cell Malignancies Non-hodgkin Lymphoma, B-cell Lymphoma, Adult B Cell ALL |
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9–Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies |
Recruiting |
NCT04035434 |
|
UCSF |
|
Stanford University |
Severe Combined Innunodeficiency (SCID) |
AMG191 Conditioning/CD34+CD90 Stem Cell Transplant Study for SCID Patients |
Recruiting |
|
|
UCSF |
|
Cellectis, SA |
Multiple Myeloma |
Phase I, open label dose‐escalation study to evaluate the safety, expansion, persistence and clinical activity of UCARTCS1A (allogeneic engineered T‐cells expressing anti‐CS1 chimeric antigen receptor), administered in patients with Relapsed/Refractory Mu |
Recruiting |
NCT04142619 |
|
UCSF |
|
Poseida Therapeutics, Inc. |
Prostate cancer |
A Phase 1 Dose Escalation and Expanded Cohort Study of P‑PSMA‑101 in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) |
Recruiting |
NCT04249947 |
|
UCSF |
|
Allo Vir, Inc. |
BK Viremia in Kidney Transplant Recipients |
Phase 2 study in patients with BK Viremia in Kidney Transplant Recipients |
Recruiting |
NCT04605484 |
|
UCSF |
|
Department of Defense |
Acute Respiratory Distress Syndrome (ARDS) |
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial of Allogenic Bone Marrow-derived Human Mesenchymal Stromal Cells for the Treatment of Acute Respiratory Distress Syndrome After Trauma |
Recruiting |
|
UCSF
& UCLA |
|
Sangamo Therapeutics |
Blood Disorder - Beta-Thalassemia |
A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) |
Recruiting |
NCT03432364 |
|
UCSF |
|
Talaris |
Transplanted Organ Rejection |
A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation (FREEDOM-1) |
Recruiting |
NCT03995901 |
|
UCSF |
|
Passage Bio Inc. |
GM1 Gangliosidosis |
A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of a Single Dose of PBGM01 Delivered into the Cisterna Magna of Pediatric Subjects Aged 4 to 24 Months with Type 1 (Early Onset Infant |
Recruiting |
NCT04713475 |
|
UCSF |
|
Case Western Reserve University |
HIV |
A Comparative Study of Autologous CD4+ T Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 versus ex vivo Expanded Unmodified Autologous CD4+ T Cells in Treated HIV-1 Infected Subjects (TRAILBLAZER) |
Recruiting |
|
|
UCSF |
|
UCSF |
Graft versus Host Disease (GvHD) |
An Expanded Access Study of Using the CLINIMACS® Device for Alpha/Beta T-Cell Depletion in Stem Cell Transplant Recipients |
Recruiting |
|
|
UCSF |
|
PACT Pharma |
Cancer – Solid Tumor |
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors |
Recruiting |
NCT03970382 |
|
UCSF and UC Davis |
|
Bioverativ Therapeutics, Inc |
Sickle Cell Disease |
A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients with Severe Sickle Cell Disease |
Recruiting |
|
|
City of Hope |
|
Adaptimmune |
Cancer - Lung |
A Phase I/ II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) |
Active, not recruiting |
|
|
City of Hope |
|
Adaptimmune |
Cancer - Sarcoma |
A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma |
Active, not recruiting |
|
|
City of Hope |
|
Kite Pharma |
Cancer - Lymphoma |
A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2) |
Active, not recruiting |
|
|
City of Hope |
|
City of Hope |
Cancer - Brain |
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas |
Active, not recruiting |
|
|
City of Hope |
|
City of Hope |
Cancer - Lymphoma (AIDS-Related) |
Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma |
Active, not recruiting |
|
UCI
& UCSD & UC Davis |
|
Aivita Biomedical |
Cancer - Brain |
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma |
Active, not recruiting |
|
|
UCI |
|
Stratetech |
Burn wounds |
StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements |
Active, not recruiting |
|
UCI
& UC Davis |
|
Humacyte |
Kidney Failure |
An Assessment of Humacyte's Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison With ePTFE Grafts as Conduits for Hemodialysis (HUMANITY) |
Active, not recruiting |
|
|
UCI |
|
Longeveron |
Aging frailty |
Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty |
Active, not recruiting |
|
UCLA
& UCI |
|
SanBio |
Brain Injury |
A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI) |
Active, not recruiting |
|
